FrancophonIA/ELRC3.0 huggingface dataset:
English: The use of combinations of levodopa and carbidopa is well established, having been in use since the mid-1970s.
Estonian: Levodopa ja karbidopa kombinatsioone on kasutatud 1970. aastate keskpaigast ja nende kasutus on hästi tõestatud.
English: The full EPAR for Levodopa/Carbidopa/Entacapone Orion can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Levodopa/Carbidopa/Entacapone Orion kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: • a history of neuroleptic malignant syndrome (a dangerous nervous system disorder usually caused by antipsychotic medicines) or rhabdomyolysis (breakdown of muscle fibres).
Estonian: • varem esinenud pahaloomuline neuroleptosündroom (ohtlik närvisüsteemi häire, mida põhjustavad tavaliselt antipsühhootikumid) või rabdomüolüüs (lihaskiudude lagunemine).
English: The maximum daily dose of Levodopa/Carbidopa/Entacapone Orion is 10 tablets, except for the tablets containing 175 mg levodopa and 43.75 mg carbidopa, for which the maximum daily dose is eight tablets, and those containing 200 mg levodopa and 50 mg carbidopa, for which it is seven tablets.
Estonian: Ravimi Levodopa/Carbidopa/Entacapone Orion suurim ööpäevane annus on 10 tabletti, välja arvatud 175 mg levodopat ja 43,75 mg karbidopat sisaldavad tabletid, mille suurim ööpäevane annus on 8 tabletti, ning 200 mg levodopat ja 50 mg karbidopat sisaldavad tabletid, mille suurim ööpäevane annus on 7 tabletti.
English: • narrow-angle glaucoma (increased pressure within the eye);
Estonian: • suletud (kinnise) nurga glaukoom (silma suurenenud siserõhk);
English: The European Commission granted a marketing authorisation valid throughout the European Union for Levodopa/Carbidopa/Entacapone Orion on 24 August 2011.
Estonian: Euroopa Komisjon andis ravimi Levodopa/Carbidopa/Entacapone Orion müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 24. augustil 2011.
English: Both carbidopa and entacapone block some of the enzymes that are involved in the breakdown of levodopa in the body: carbidopa blocks the enzyme dopa decarboxylase, and entacapone blocks the enzyme catechol-O-methyl transferase (COMT).
Estonian: Nii karbidopa kui ka entakapoon blokeerivad teatud ensüüme, mis osalevad levodopa lagundamises organismis: karbidopa blokeerib ensüümi dopadekarboksülaasi ja entakapoon blokeerib ensüümi katehhool-O-metüültransferaasi (COMT).
English: Serious side effects which have been reported much less often include gastrointestinal haemorrhage (bleeding in the gut) and angioedema (swelling under the skin of face or limbs).
Estonian: Harvemini teatatud rasked kõrvalnähud hõlmavad enamasti seedetrakti verejooksu ja angioödeemi (nahaalune turse näol või jäsemetel).
English: The CHMP decided that Levodopa/Carbidopa/Entacapone Orion's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et ravimi Levodopa/Carbidopa/Entacapone Orion kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: It is available as a range of tablets in seven strengths, containing 50 to 200 mg levodopa and 12.5 to 50 mg carbidopa.
Estonian: Seda turustatakse seitsmes tugevuses tablettidena, mis sisaldavad levodopat annuses 50-200 mg ja karbidopat annuses 12,5-50 mg. Kõik tabletid sisaldavad 200 mg entakapooni.
English: In patients with Parkinson's disease, the cells in the brain that produce dopamine (a substance used to transmit signals between nerve cells that help to control muscle movement) begin to die and the amount of dopamine in the brain decreases.
Estonian: Parkinsoni tõvega patsiendil hakkavad dopamiini (närvisignaale vahendav aine, mis aitab koordineerida liigutusi) tootvad rakud hävima ning dopamiini hulk ajus väheneb.
English: The strength of Levodopa/Carbidopa/Entacapone Orion that the patient should use is based on the amount of levodopa they need to control their symptoms.
Estonian: Ravimi Levodopa/Carbidopa/Entacapone Orion tableti tugevus, mida patsient peab kasutama, sõltub sümptomite leevendamiseks vajalikust levodopa kogusest.
English: The studies showed that Levodopa/Carbidopa/Entacapone Orion is bioequivalent to the separate tablets.
Estonian: Uuringud näitasid, et Levodopa/Carbidopa/Entacapone Orion on eraldi tablettidega bioekvivalentne.
English: For more information about treatment with Levodopa/Carbidopa/Entacapone Orion, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Levodopa/Carbidopa/Entacapone Orion toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Levodopa/Carbidopa/Entacapone Orion is used in patients who are being treated with a combination of levodopa and an inhibitor of dopa decarboxylase (two standard treatments for Parkinson's disease) but are having ‘fluctuations' towards the end of the period between two doses of their medication.
Estonian: Ravimit Levodopa/Carbidopa/Entacapone Orion kasutatakse patsientidel, keda ravitakse levodopa ja dopadekarboksülaasiinhibiitori (kaks Parkinsoni tõve standardravimit) kombinatsiooniga, kui patsientidel esineb ebakindlaid sümptomeid kahe ravimiannuse vahelise aja lõpus.
English: They are linked with a reduction in the effect of levodopa, when the patient experiences sudden switches between being ‘on' and able to move, and being ‘off' and having difficulty moving about.
Estonian: Kõikumised on seotud levodopa toime vähenemisega, mille korral patsiendil hakkavad liikumisvõime ja liikumisraskused järsku vahelduma.
English: The most common side effects with Levodopa/Carbidopa/Entacapone Orion (seen in more than 1 patient in 10) are dyskinesia (uncontrollable movements), muscle pain, diarrhoea and nausea (feeling sick) and harmless urine discoloration.
Estonian: Ravimi Levodopa/Carbidopa/Entacapone Orion kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on düskineesia (sundliigutused), lihasevalu, kõhulahtisus ja iiveldus ning uriini kahjutu värvimuutus.
English: Levodopa/Carbidopa/Entacapone Orion is used when these fluctuations cannot be treated with the standard combination alone.
Estonian: Ravimit Levodopa/Carbidopa/Entacapone Orion kasutatakse juhul, kui sümptomite ebakindlust ei saa ravida ainult standardravimikombinatsiooniga.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levodopa/Carbidopa/Entacapone Orion.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Each Levodopa/Carbidopa/Entacapone Orion tablet contains one complete dose of levodopa, in seven strengths, with corresponding amounts of carbidopa and entacapone to improve its effectiveness.
Estonian: Iga ravimi Levodopa/Carbidopa/Entacapone Orion tablett sisaldab üht täielikku levodopa annust (seitsme eri tugevusega) ning selle toime tugevdamiseks vastavates kogustes karbidopat ja entakapooni.
English: The company carried out ‘bioequivalence' studies to show that taking Levodopa/Carbidopa/Entacapone Orion produces the same levels of levodopa, carbidopa and entecapone in the blood as taking separate tablets containing entacapone and the combination of levodopa and carbidopa.
Estonian: Ettevõte viis läbi bioekvivalentsuse uuringud, millega tõendas, et Stalevo kasutamisel on levodopa, karbidopa ja entakapooni sisaldus veres samasugune kui toimeainete võtmisel eraldi entakapooni tablettidena ning kombineeritud levodopa ja karbidopa tablettidena.
English: This is a summary of the European public assessment report (EPAR) for Levodopa/Carbidopa/Entacapone Orion.
Estonian: See on ravimi Levodopa/Carbidopa/Entacapone Orion Euroopa avaliku hindamisaruande kokkuvõte.
English: All of the active substances in Levodopa/Carbidopa/Entacapone Orion work to restore the levels of dopamine in the parts of the brain that control movement and co-ordination.
Estonian: Ravimis Levodopa/Carbidopa/Entacapone Orioni sisalduvate toimeainete mõjul taastub dopamiini sisaldus aju osades, mis juhivad liigutusi ja koordinatsiooni.
English: Levodopa/Carbidopa/Entacapone Orion must not be used in people who are hypersensitive (allergic) to levodopa, carbidopa, entacapone or any of the other ingredients.
Estonian: Ravimit Levodopa/Carbidopa/Entacapone Orion ei tohi kasutada patsiendid, kes on levodopa, karbidopa, entakapooni või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Levodopa/Carbidopa/Entacapone Orion tablets should be taken whole, with or without food.
Estonian: Ravimi Levodopa/Carbidopa/Entacapone Orion tabletid tuleb neelata tervena, koos toiduga või ilma.
English: Levodopa/Carbidopa/Entacapone Orion must not be used together with other medicines that belong to the group ‘monoamine oxidase inhibitors' (a type of antidepressant).
Estonian: Ravimit Levodopa/Carbidopa/Entacapone Orion ei tohi kasutada koos teiste monoaminooksüdaasiinhibiitorite (antidepressantide liik) rühma ravimitega.
English: Levodopa/Carbidopa/Entacapone Orion is a medicine that contains three active substances: levodopa, carbidopa and entacapone.
Estonian: Levodopa/Carbidopa/Entacapone Orion on ravim, mis sisaldab toimeainetena levodopat, karbidopat ja entakapooni.
English: Levodopa/Carbidopa/Entacapone Orion is used to treat adults with Parkinson's disease.
Estonian: Ravimit Levodopa/Carbidopa/Entacapone Orion kasutatakse Parkinsoni tõvega täiskasvanud patsientide raviks.
English: The company used some of the data from Comtess/Comtan to support the use of Levodopa/Carbidopa/Entacapone Orion and presented data from the published literature for levodopa and carbidopa.
Estonian: Ettevõte esitas ravimi Levodopa/Carbidopa/Entacapone Orion kasutamise toetuseks ravimi Comtess/Comtan andmed ning levodopa ja karbidopa kohta avaldatud kirjandusandmed.
English: Other information about Levodopa/Carbidopa/Entacapone Orion
Estonian: Muu teave ravimi Levodopa/Carbidopa/Entacapone Orion kohta
English: They should be used with caution in patients with mild to moderately reduced liver function or severely reduced kidney function.
Estonian: Kerge või mõõduka maksatalitluse häire või raske neerupuudulikkusega patsiendid peavad ravimit kasutama ettevaatlikult.
English: For the full list of all side effects reported with Levodopa/Carbidopa/Entacapone Orion, see the package leaflet.
Estonian: Ravimi Levodopa/Carbidopa/Entacapone Orion kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: EPAR summary for the public levodopa/carbidopa/entacapone
Estonian: Kokkuvõte üldsusele levodopa/karbidopa/entakapoon
English: What is the risk associated with Levodopa/Carbidopa/Entacapone Orion?
Estonian: Mis riskid ravimiga Levodopa/Carbidopa/Entacapone Orion kaasnevad?
English: Why has Levodopa/Carbidopa/Entacapone Orion been approved?
Estonian: Miks Levodopa/Carbidopa/Entacapone Orion heaks kiideti?
English: What is Levodopa/Carbidopa/Entacapone Orion?
Estonian: Mis on Levodopa/Carbidopa/Entacapone Orion?
English: How does Levodopa/Carbidopa/Entacapone Orion work?
Estonian: Kuidas Levodopa/Carbidopa/Entacapone Orion toimib?
English: How has Levodopa/Carbidopa/Entacapone Orion been studied?
Estonian: Kuidas ravimit Levodopa/Carbidopa/Entacapone Orion uuriti?
English: How is Levodopa/Carbidopa/Entacapone Orion used?
Estonian: Kuidas ravimit Levodopa/Carbidopa/Entacapone Orion kasutatakse?
English: See the summary of product characteristics (also part of the EPAR) for full instructions on how patients should be switched to Levodopa/Carbidopa/Entacapone Orion, and on how the dose is adjusted during treatment.
Estonian: Üksikasjalik teave, kuidas patsient üle viia ravimile Levodopa/Carbidopa/Entacapone Orion ja kuidas annust ravi ajal kohandada, on esitatud ravimi omaduste kokkuvõttes, mis on samuti Euroopa avaliku hindamisaruande osa.
English: What benefit has Levodopa/Carbidopa/Entacapone Orion shown during the studies?
Estonian: Milles seisneb uuringute põhjal ravimi Levodopa/Carbidopa/Entacapone Orion kasulikkus?
English: 3 pre-filled pens
Estonian: 3 pensüstlit
English: Invented name Strength Pharmaceutical Form Route of administration
Estonian: TugevusRavimvorm Manustamistee
English: What happens
Estonian: Mis toimub
English: *Patients who have not received transfusions in the prior 60 days.
Estonian: * Patsiendid, kes eelneva 60 päeva jooksul ei ole transfusioone saanud.
English: Do not thaw the product until it is ready to be used.
Estonian: Ärge sulatage toodet enne, kui ollakse valmis selle kasutamiseks.
English: ***No patients are currently evaluable for these endpoints.
Estonian: *** Nende tulemusnäitajate hindamiseks praegu patsiente ei ole.
English: All reactions resolved.
Estonian: Kõik reaktsioonid möödusid.
English: This information is intended for doctors only.
Estonian: See teave on ainult arstidele.
English: When 20 patients have been treated with 6 months follow-up
Estonian: Kui 6-kuulise järelkontrolliperioodiga on ravitud 20 patsienti
English: You will remain in the hospital for approximately 3-6 weeks
Estonian: Teid jäetakse umbes 3...6 nädalaks haiglasse
English: (First Infusion Bag)
Estonian: (esimene infusiooni kott)
English: Patient ID: COI ID:
Estonian: Patsiendi ID: COI ID:
English: As this medicine will be given by a qualified doctor, they are responsible for the correct storage of the medicine before and during its use, as well as for its correct disposal.
Estonian: Kuna seda ravimit tohib manustada kvalifitseeritud arst, siis vastutab ta ka selle ravimi korrektse säilitamise eest enne ja pärast selle kasutamist ning selle korrektse hävitamise eest.
English: The selection of the treatment centres will be conducted in collaboration with national health authorities as appropriate.
Estonian: Ravikeskused valitakse vastavalt vajadusele koostöös riiklike tervishoiuasutustega.
English: All other bleeding events were nonserious.
Estonian: Teised veritsusjuhud ei olnud rasked.
English: If you are concerned about having children, you should discuss this with your doctor before treatment.
Estonian: Kui teile tekitab laste saamine muret, peaksite seda arutama oma arstiga enne ravi.
English: To recover and be monitored until your doctor is satisfied that it is safe for you to leave the hospital.
Estonian: Et taastuksite ja teid saaks jälgida, kuni teie arst otsustab, et teil on ohutu haiglast lahkuda.
English: UNIQUE IDENTIFIER - 2D BARCODE
Estonian: AINULAADNE IDENTIFIKAATOR - 2D- vöötkood
English: • excess water in the body
Estonian: • liigne vesi kehas
English: Given the small patient population and size of cohorts, adverse reactions in the table below do not provide a complete perspective on the nature and frequency of these events.
Estonian: Arvestades väikest patsiendipopulatsiooni ja kohortide suurust, ei anna järgmises tabelis toodud kõrvaltoimed täit perspektiivi nende sündmuste olemusest ja esinemissagedusest.
English: Your doctor will advise you if and when you should start taking these medicines after Zynteglo infusion.
Estonian: Teie arst annab teile nõu, kas ja millal te peate neid ravimeid võtma pärast Zynteglo infusiooni.
English: Overall results
Estonian: Üldised tulemused
English: Pharmacotherapeutic group: Other haematological agents, ATC code: not yet assigned Mechanism of action
Estonian: Farmakoterapeutiline rühm: teised hematoloogilised ravimid, ATC-kood: ei ole veel omistatud
English: Very Common (≥10%)
Estonian: Väga sage (≥ 10%)
English: You should carry the Patient Alert Card with you at all times and show it to your doctor or nurse when you see them or if you are admitted to the hospital.
Estonian: Kandke seda patsiendi teabekaarti endaga alati kaasas ja näidake seda oma arstile või meditsiiniõele, kui nende vastuvõtule lähete, või kui teid võetakse haiglasse.
English: Zynteglo must not be re-frozen.
Estonian: Zynteglot ei tohi uuesti külmutada.
English: Frequencies are defined as: very common (≥1/10), and common (≥1/100 and <1/10).
Estonian: Esinemissagedus on määratletud järgmiselt: väga sage (≥1/10) ja sage (≥1/100 kuni <1/10).
English: During the long-term follow-up, your doctor will monitor you for any signs of leukaemia or lymphoma.
Estonian: Pikaajalise järelkontrolli ajal jälgib teie arst teid leukeemia või lümfoomi tunnuste suhtes.
English: Common (≥1% - <10%)
Estonian: Sage (≥ 1%...< 10%)
English: - Read the Patient Alert Card carefully and follow the instructions on it.
Estonian: - Lugege seda patsiendi teabekaarti hoolikalt ja järgige kirjas olevaid juhiseid.
English: • irregular menstruation
Estonian: • ebaregulaarne menstruatsioon
English: • Physician educational material • Patient information pack
Estonian: • arsti koolitusmaterjal, • patsiendi teabepakett.
English: The blood stem cells can then be collected by a machine that separates blood components (apheresis machine).
Estonian: Seejärel on võimalik vere tüvirakke koguda masinaga, mis eraldab verekomponente (afereesiseade).
English: It is therefore advised to cryopreserve semen or ova before treatment if possible.
Estonian: Seega on soovitatav võimalusel krüosäilitada seemnerakke või munarakke enne ravi.
English: Patients are expected to enrol in a registry and will be followed long term in the registry in order to better understand the long-term safety and efficacy of Zynteglo.
Estonian: Patsiendid peab kandma registrisse ning neid jälgitakse seejärel registris pikka aega, et paremini mõista Zynteglo pikaajalist ohutust ja efektiivsust.
English: This information is provided in the Patient Alert Card which should be given to the patient after treatment.
Estonian: See teave on toodud patsiendi teabekaardil, mis tuleb patsiendile anda pärast ravi.
English: Events were mild and included abdominal pain, hot flush, dyspnoea, and non-cardiac chest pain in 9.5%, 2.4%, 2.4%, and 2.4% of patients, respectively.
Estonian: Nähud olid kerged, nende hulgas olid kõhuvalu, kuumahood, düspnoe ja mittekardiaalne rindekerevalu vastavalt 9,5%-l, 2,4%-l, 2,4%-l ja 2,4%-l patsientidest.
English: • decreased testosterone
Estonian: • vähenenud testosterooni tase
English: • low level of red and white blood cells, sometimes with a fever
Estonian: • punaseid ja valgeid vererakke on vähe, vahel koos palavikuga
English: If a third day of collection was needed, plerixafor and G-CSF dosing was extended to Day 6.
Estonian: Kui kogumiseks oli vaja 3. päeva, siis pikendati pleriksafoori ja G-CSF-i annustamist 6. päevale.
English: Date of first authorisation: 29 May 2019
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 29. mai 2019
English: Zynteglo has not been studied in patients with HIV-1, HIV-2, HTLV-1, or HTLV-2.
Estonian: Zynteglot ei ole uuritud patsientidel, kellel on HIV-1, HIV-2, HTLV-1 või HTLV-2.
English: Magyarország, Malta, Norge, Österreich, Polska, Portugal, România, Slovenija, Slovenská republika, Suomi/Finland, Sverige bluebird bio (Netherlands) B.V.
Estonian: België/Belgique/Belgien, България, Česká republika, Danmark, Eesti, Ελλάδα, España, Hrvatska, Ireland, Ísland, Κύπρος, Latvija, Lietuva, Luxembourg/Luxemburg, Magyarország, Malta, Norge, Österreich, Polska, Portugal, România, Slovenija, Slovenská republika, Suomi/Finland, Sverige bluebird bio (Netherlands) B.V.
English: Your doctor will tell you when your platelet count has recovered to normal levels.
Estonian: Teie arst ütleb teile, kui teie trombotsüütide arv on taastunud normaalseni.
English: The minimum recommended dose is the same for adults and adolescents 12 years of age and older.
Estonian: Täiskasvanute ning 12-aastaste ja vanemate noorukite väikseim soovitatav annus on sama.
English: Risks associated with TDT and iron overload
Estonian: TDT ja raua ülekoormusega seotud riskid
English: Contents of the pack and other information What Zynteglo contains
Estonian: Pakendi sisu ja muu teave Mida Zynteglo sisaldab
English: Other medicines and Zynteglo
Estonian: Muud ravimid ja Zynteglo
English: Patients seropositive for human immunodeficiency virus (HIV) or human T-lymphotropic virus (HTLV)
Estonian: Inimese immuunpuudulikkuse viiruse (HIV) või inimese T-lümfotroopse viiruse (HTLV) suhtes seropositiivsed patsiendid
English: A clear to slightly cloudy, colourless to yellow or pink dispersion.
Estonian: Läbipaistev kuni kergelt hägune, värvitu kuni kollane või roosa dispersioon.
English: You will be given a Patient Alert Card which contains important safety information that you need to know about your treatment with Zynteglo.
Estonian: Teile antakse patsiendi teabekaart, mis sisaldab olulist ohutusteavet, mida te peate teadma oma ravi kohta Zyntegloga.
English: Zynteglo is intended for autologous use (see section 4.4) and should only be administered once.
Estonian: Zynteglo on mõeldud autoloogseks kasutamiseks (vt lõik 4.4) ning seda tohib manustada ainult üks kord.
English: Thawing of each infusion bag takes approximately 2 to 4 minutes.
Estonian: Ühe infusioonikoti sulatamine võtab umbes 2 kuni 4 minutit.
English: Irradiation could lead to inactivation of the product.
Estonian: Kiiritamine võib ravimi inaktiveerida.
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, tell your doctor before you are given this medicine.
Estonian: Kui te olete rase, imetate või arvate end olevat rase või kavatsete rasestuda, pidage enne selle ravimi saamist nõu oma arstiga.
English: This means that your blood may not be able to clot as well as normal and you may be prone to bleeding.
Estonian: See tähendab võimalust, et teie veri ei suuda tavapäraselt hüübida ning teil võivad kergemini tekkida veritsused.
English: These may be signs of a serious liver condition called veno-occlusive disease.
Estonian: Need võivad olla tõsise maksahäire, mida nimetatakse venooklusiivseks haiguseks, tunnused.
English: This leaflet was last revised in <{MM/YYYY}>
Estonian: Infoleht on viimati uuendatud {KK.AAAA}>
English: - The other ingredients are a solution used to preserve frozen cells and sodium chloride.
Estonian: - Teised koostisosad on lahus, mida kasutatakse külmutatud rakkude säilitamiseks ja naatriumkloriid.
English: Infusion related reactions to Zynteglo were observed in 11.9% of patients and occurred on the day of Zynteglo infusion.
Estonian: Infusiooniga seotud reaktsioone Zynteglole täheldati 11,9%-l patsientidest ja need tekkisid Zynteglo infundeerimise päeval.
English: • numbness and pain in hands and feet
Estonian: • tuimus ja valu kätes ja jalgades
English: Some iron chelators are myelosuppressive.
Estonian: Mõned raua kelaatorid on müelosupressiivsed.
English: Do not re-freeze after thawing.
Estonian: Pärast sulatamist mitte uuesti külmutada.
English: Strength cells/mL)
Estonian: Tugevus rakku/ml)
English: Any blood products required within the first 3 months after Zynteglo infusion should be irradiated.
Estonian: Mistahes veretooted, mida läheb esimesel 3 kuul pärast Zynteglo infusiooni vaja, tuleb kiiritada.
English: Local biosafety guidelines applicable for such products should be followed.
Estonian: Järgida tuleb sellistele preparaatidele kohalduvaid kohalikke bioohutuse nõudeid.
English: • chest pain not due to a heart problem
Estonian: • rindkerevalu, mida ei põhjusta südameprobleem
English: After carefully removing the outer metal container, thaw each infusion bag at 37°C in a water bath or dry bath for approximately 2-4 minutes.
Estonian: Kui väline metallkonteiner on ettevaatlikult eemaldatud, sulatage igat infusioonikotti vesivannis või kuivvannis temperatuuril 37 °C umbes 2...4 minutit.
English: Zynteglo is made specifically for you, using your own blood stem cells.
Estonian: Zynteglo valmistatakse spetsiaalselt teile, kasutades teie enda vere tüvirakke.
English: What you need to know before you are given Zynteglo You must not be given Zynteglo if you:
Estonian: Mida on vaja teada enne, kui teile antakse Zynteglot Teile ei tohi Zynteglot anda, kui te: